Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- APPLIKATE TECHNOLOGIES, INC.
- Proposal award date
- 2017-08-01
- Contract end date
- 2019-07-31
- UEI
- ZB4HQTBNJ6D4
- Solicitation number
- PA16-302
- Topic code
- NCI
Research abstract
Project Summary and Relevance
The aim of this Phase II SBIR proposal from Applikate TechnologiesLLCis to build on the successful
completion of our Phase I milestones with the designconstructionand testing of prototype devices and
software for implementing the ClearView tissue histology system in clinical settings by laboratory personnelClearView is a novel approach to performing complete and non destructive imaging of tissue specimens for
lung and other cancersLung cancer biopsy diagnosis error rates may run as high asAlthough there are many potential
sources of errorimportant aspects relate to limitations of current methods for tissue processing and analysisStandard methods limit the amount of tissue that can be visualized by the diagnostic pathologist and that is
available for personalized medicine testingThey also are not amenable to consultation with off site experts
and are dependent on manual processing by adequately trained histotechnologistsApplikate Technologies
has developed ClearViewa completenon destructivefasttissue processing and imaging approach to
histology that improves on limits of slide based histology by providing complete tissue visualizationreducing
artifacts of preparationpermitting improved quantitative interpretationshowing additional growth pattern
informationand eliminating extensive manual preparationThe ClearView system yields images that arein
many casessuperior even to traditionally processed histology slides with pseudo coloring that is virtually
indistinguishable from conventional stainingall in an entirely digital format ready for remote access and
storageAnd ClearView is fast enough to provide diagnostic quality images in under two hours for same day
diagnosisWe have also demonstratedduring our Phase I fundingthat the ClearView process yields orders of
magnitude more DNA for molecular analyses and is compatible with immunohistochemical stainingFurthermorethe methodology is applicable not only to lung cancer diagnosisbut to evaluation of practically
any solid tissue cancerThe specific aims of the proposal are toDevelop an application specifichigh speed multiphoton
microscope and associated softwareDevelop the ClearView prototype tissue chamberandDevelop the
ClearView prototype tissue processorThese three elementsalong with proprietary reagentsform the core of
the ClearView systemFollowing in house testingtwo complete prototype systems will be placed in two
hospitalsone a large tertiary care center and the second a mid sized hospitalfor on site testing and feedback
by non expert users in a clinical settingSuccessful completion of these aims will set the stage for a Phase III
transition to regulatory approval and provide a proven platform for early implementation through service work
for academic research and clinical research groups
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
6 SBIR/STTR records share this UEI (2014–2023). Reported award amounts total $7,807,172. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards